Analysts think AMRN stock price could increase by 30%
Jul 31, 2024, 6:25 AM
-22.82%
What does AMRN do
Amarin Corp. Plc, a biopharmaceutical company, specializes in developing and commercializing therapeutics aimed at enhancing cardiovascular health, primarily through its lead product, Vascepa. Vascepa, used to lower triglyceride levels in adults with severe hypertriglyceridemia, is distributed mainly to wholesalers and pharmacies.
4 analysts think AMRN stock price will increase by 29.89%. The current median analyst target is $1.02 compared to a current stock price of $0.79. The lowest analysts target is $1.01 and the highest analyst target is $1.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
